**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6373**

**Columns: TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (5): Colorectal cancer

**Cancer stem cells in colorectal cancer from pathogenesis to therapy: Controversies and perspectives**

Fanali C *et al*. Colorectal cancer stem cells

Caterina Fanali, Donatella Lucchetti, Marisa Farina, Maddalena Corbi, Valerio Cufino, Achille Cittadini, Alessandro Sgambato

**Caterina Fanali, Donatella Lucchetti, Marisa Farina, Maddalena Corbi, Valerio Cufino, Achille Cittadini, Alessandro Sgambato,** Istituto di Patologia Generale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

**Author contributions:** Fanali C, Lucchetti D and Farina Mcontributed equally to this work; All Authors contributed to manuscript preparation; Sgambato A supervised the work and was responsible for the final editing.

**Correspondence to:** **Alessandro Sgambato, MD, PhD,** Istituto di Patologia Generale, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy. asgambato@rm.unicatt.it

**Telephone:** +39-6-3016619 **Fax:** +39-6-3012753

**Received:** October 15, 2011  **Revised:** November 20, 2013

**Accepted:** January 2, 2014

**Published online:**

**Abstract**

Colorectal cancer remains one of the most common and lethal malignancies worldwide despite the use of various therapeutic strategies. A better understanding of the mechanisms responsible for tumor initiation and progression is essential for the development of novel, more powerful therapies. The traditional, so-called “stochastic model” of tumor development, which assumes that each cancer cell is tumorigenic, has been deeply challenged during the past decade by the identification of cancer stem cells (CSCs), a biologically distinct subset of cells within the bulk of tumor mass. This discovery led to the development of the hierarchical model of tumorigenesis which assumes that only CSCs have the ability to initiate tumor growth, both at primary and metastatic sites. This model implies that the elimination of all CSCs is fundamental to eradicate tumors and that failure to do so might be responsible for the occurrence of relapses and/or metastases frequently observed in the clinical management of colorectal cancer patients. Identification and isolation of CSCs is essential for a better understanding of their role in the tumorigenetic process and for the development of CSC-specific therapies. Several methods have been used for this purpose and many efforts have been focused on the identification of specific CSC-surface markers. This review provides an overview of the proposed roles of CSC in human colorectal tumorigenesis focusing on the most important molecules identified as CSC-specific markers in colorectal cancer and on the potential strategies for the development of CSC-targeted therapy.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Colorectal cancer; Cancer stem cells; Tumorigenesis; Cancer therapy; Prognostic marker

**Core tip:** A better understanding of the mechanisms responsible for tumor initiation and progression is essential for the development of novel, more powerful therapies for colorectal cancer patients. In this paper, we review the basic concepts of both the traditional “stochastic”, and of the more recent, “hierarchical” models of tumor development. We then introduce the so-called cancer stem cells (CSCs) and provides an overview of the proposed roles of CSC in human colorectal tumorigenesis focusing on the most important molecules identified as CSC-specific marker in colorectal cancer and on the potential strategies for the development of CSC-targeted therapy.

Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A, Sgambato A. Cancer stem cells in colorectal cancer from pathogenesis to therapy: Controversies and perspectives.

**Available from:** URL: http://www.wjgnet.com/1007-9327/

**DOI:** http://dx.doi.org/10.3748/

**INTRODUCTION**

Colorectal cancer (CRC) is one of the most common malignancies in Western countries and, although it can cause symptoms at a very early stage and can be easily detected and treated by resection, it remains the second leading cause of cancer-related death in Europe and the third in the United States with a median survival time ranging from less than one to more than five years depending on the stage of disease at the diagnosis and the surgical techniques and/or chemotherapy used, especially for metastatic CRC[1]. Several studies have underlined the role of environmental and lifestyle factors in colorectal carcinogenesis showing an increase in CRC incidence in parallel with economic development and adoption of a western lifestyle in several countries.

CRC originates from epithelial cells lining the gastrointestinal tract which undergo sequential mutations in specific DNA sequences that disrupt normal mechanisms of proliferation and self-renewal[2]. The intestinal tract consists of the small intestine (duodenum, jejunum and ileum) and the large intestine or colon, which comprises the cecum, ascending, transverse and descending colon, sigmoid colon, rectum and anal canal. The innermost layer of the colon wall (mucosa) is lined by an absorptive and secretory columnar epithelium which is folded into finger-like invaginations incorporated in the submucosa connective tissue to form the functional unit of the intestine, the crypts of Lieberkühn (Figure 1). Normal human colon consists of millions of crypts containing about 2000 cells and comprising the differentiated cell lineages (enterocytes, enteroendocrine cells and goblet cells). A fourth differentiated type, the Paneth-like cells, resides at the bottom of colon crypts and has been shown to synthesize and secrete a variety of antimicrobial factors[3]. Differentiated colon epithelial cells are subjected to a massive turnover throughout life, being replaced approximately every 5 d. The ability to maintain tissue homeostasis is provided by a subset of self-renewing undifferentiated, multipotent stem cells which generate transit-amplifying cells, committed progenitors[3]. These cells lie towards the bottom of the crypt in the proliferative zone and through an asymmetric division are responsible for generating all epithelial cell types along the crypt-villus axis. The number of long-lived stem cells per each crypt is commonly estimated to be between 4 and 6 cells even if the precise number and what controls their numbers remain uncertain(Figure 1). Two distinct populations of putative stem cells have been identified at the base of an intestinal crypts. A population is marked by the expression of the G-protein receptor Lgr5, a Wnt gene target, and positioned just above the Paneth cells at the crypt base, while the other resides at +4 position from the bottom of the crypt and are marked by the expression of the polycomb group gene Bmi1 and the telomerase reverse transcriptase, Tert[4,5] Both cell types have been demonstrated to fulfill the criteria for stem cells (pluripotency and self-renewal capacity)[4,5]. Several studies are trying to understand whether their stem cell characteristics are intrinsically determined or determined by the environmental niche. It is widely accepted, however, that stem cell niches are formed by cellular components and extracellular matrix which create a special microenvironment important for the maintenance of stem cells properties, protect stem cells from differentiating and apoptotic stimuli and regulate the balance between proliferation and differentiation through direct interaction and secretion of various cytokines and growth factors[6]. The stem cells self-renewal and differentiation are also influenced by components in the crypt lumen derived from bacteria or epithelial cells as well as by morphogenetic factors secreted by intestinal sub-epithelial myofibroblasts[7].

Mounting evidence suggests that stem cells might play an important role in the process of tumor development being able to acquire a tumorigenic potential and giving rise to the so-called cancer stem cells whose potential role as tumor initiating cells as well as targets of cancer therapies is discussed in this review.

***Models of colorectal tumorigenesis***

CRC has been an ideal model to study the malignant progression because different phases of the same malignancy often coexist within the same patient and have provided basic information concerning human tumorigenesis. Although most of the CRCs are sporadic, a small percentage arises in the setting of inherited syndromes, such as familial adenomatous polyposis (FAP), juvenile polyposis syndrome (JPS) and hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome), which have been extremely useful for our understanding of human colorectal tumorigenesis. The study of these hereditary cancer syndromes, as well as of sporadic CRC, has led to a detailed knowledge of the sequence of genetic mutations underlying CRC development with the formulation of a model of multistep carcinogenesis which has been subsequently extended to the majority of human cancers[8]. It is now widely accepted that, regardless of the starting event, CRC is the end result of a variable concatenation of genetic alterations that lead a normal colonic epithelial cell to transform into a colon cancer cell. According to the model of colorectal tumorigenesis, initially proposed by Fearon *et al*[8] (also known as the adenoma-cancer sequence), CRC development occurs through a series of steps morphologically identifiable: initially there is localized proliferation of the colon epithelium with the formation of small adenomas which progressively grow with dysplasia and ultimately progress into invasive carcinomas. Most of the CRC is characterized by a dysfunctional regulation of the Wnt/β-catenin pathway, essential for the development of the normal colonic mucosa[9]. About 80% of patients with FAP have loss or mutation in the APC (adenomatous polyposis coli) gene which encodes a protein that participates to the formation of a complex that regulates the stability of β-catenin. In the absence of Wnt ligand this complex retains the β-catenin which is phosphorylated and degraded by the proteasome. When the APC molecule is mutated, the cytosolic β-catenin levels are stabilized and the protein can then accumulate in the nucleus where it serves as a coactivator for the Tcf family of transcription factors which activate the expression of specific target genes including some metalloproteinases, the fibronectin and oncogenes such as c-myc and cyclin D1[10]. The study of JPS, a condition that predisposes to hamartomatous gastrointestinal polyps formation, has revealed the important role of SMAD/BMP (bone morfogenetic protein) in intestinal architecture. JPS is due to germline mutations in the SMAD4 gene in 15%-20% of cases and to mutations in the gene encoding BMP receptor 1A in 25%-40% of cases. SMAD4 is an intracellular signal transducing transcription factor shared by the Transforming growth factor β, activin and BMP pathways. BMP family ligands are expressed by the villus mesenchyme, while epithelial cells display nuclear phosphorylated SMADs, implicating these cells as terminal recipients of the signal[11]. Wnt and BMP pathways interact to control intestinal stem cells self-renewal through the PTEN-Akt pathway that helps to control the nuclear localization of the Wnt pathway effector β-catenin[12]. Interaction between Wnt and Notch pathway, which maintains proliferative cells in normal cripts, is also deregulated in tumorigenesis[9]. Wnt signaling, Hedgehog, BMP, Notch and Platelet-derived growth factors are involved in the process of epithelial to mesenchymal transition and invasion[7].

According to the traditional model of carcinogenesis a tumor may arise from any cell of the body following a series of mutations conferring them an unlimited proliferation potential. The resulting mutated progeny is subject to additional mutations, due to genetic instability, and epigenetic changes, promoting the appearance of a genetically heterogeneous tumor mass.

This view has been initially integrated in the so-called “stochastic model” of tumor development which assumes that each cancer cell isolated from the bulk tumor is tumorigenic and thus has the ability to proliferate extensively and regenerate a tumor with the same characteristics of the original tumor when injected in immunodeficient mice (Figure 2).

The presence of cell types with various degrees of differentiation within human CRC[13] and of a stem cells overpopulation at the botton crypt during the process of adenoma development in patients with FAP, has suggested a hierarchical model of CRC development as opposed to the stochastic model. According to this model, only a small fraction of tumor cells would be able to support the neoplastic proliferation, the part that retains the characteristics of stem cells and that in itself has a unlimited proliferative potential. The tumors would be organized as a normal tissues with a rare subpopulation of undifferentiated cells having the unique biological properties necessary for tumor initiation, maintenance, and spreading[14] (Figure 2). These cancer cells displaying stemness features have been defined cancer stem cells (CSCs) and, similarly to normal stem cells, would be located in a niche with mesenchymal cells that would ensure their survival in a secure environment, regulating their proliferation through secretion of soluble factors[15]. According to this model, these slow proliferating CSCs display self-renewal, unlimited proliferative potential and multipotency and would be responsible for tumor initiation and development as well as local relapses and metastases. Moreover, CSCs would be highly resistant to traditional antineoplastic agents due to the expression of detoxifying enzymes, drug transporters and DNA repair mechanisms[15].

The origin of CSCs remains unclear and it is still object of a debate whether they derive from more mature cells that reacquire stem cell properties during tumor formation or are the direct progeny of mutated stem cells[15] (Figure 2). The discovery of stem cells in the majority of normal tissues, including colon crypts, supports the hypothesis that normal stem cells might represent a possible target for tumorigenic mutations and the origin of CSCs due to both their longevity and their ability to self-renewal. Furthermore, the fact that despite the emergence of new targeted agents and the use of various therapeutic combinations, none of the options currently available is curative for patients with CRC strengthens the model of CSCs and supports the hypothesis that most of the currently available therapies only target the bulk of the tumor mass (mainly constituted by proliferating cells) while sparing the rare, quiescent CSCs which would be able to re-initiate tumor growth thus giving origin to both recurrences and metastases (Figure 3). This hypothesis supports the needs of a better characterization of CSCs with the aim to develop CSCs-specific therapies which might represent a great advantage in the fight against cancer.

**COLORECTAL CANCER STEM CELLS MARKERS**

Several methods have been proposed in the last years for the identification and isolation of CSC but some of them require a great technical expertise, are extremely time-consuming or involve the use of animals. Thus, many efforts have been focused on the identification of specific CSCs-surface markers which would allow the identification, and likely the isolation, of CSCs using easier antibody-based techniques such as immunostaining, Fluorescence-activated cell sorting (FACS) analysis, cell sorting, immunomagnetic separation, *etc*. One of the first CSCs markers identified in human CRC was the CD133, a pentaspan transmembrane glycoprotein which was shown to specifically mark tumor-initiating cells within the bulk of human CRC[16,17]. In the same period Dalerba et al found that CD133+ cells population also express other specific stem cell antigens such as EpCAM, CD44 and CD166 which can help to identify CSCs while a subsequent study showed that CD133 colon cancer cell spheroids grown *in vitro* also expressed Msi-1[18]. Other potential markers of CRC stem cells have been more recently identified including CD29, CD24 and Lgr5[19-21] (Table 1).

***CD133/Prominin-1***

Human CD133, also known as Prominin-1, is a 120 kDa cholesterol-interacting pentaspan-transmembrane glycoprotein that belongs to the Prominin family. CD133 protein consists of an extracellular N-terminal domain, a cytoplasmic C-terminus that contains five tyrosine residues including a tyrosine phosphorylation consensus site, two small cysteine-rich cytoplasmic loops and two large extracellular loops containing four consensus sequences for N-linked glycosilation[22] (Figure 4).

CD133 was first recognized as a surface protein marker of a subset of hematopoietic stem cells and progenitor cells[22] and of bone marrow–derived circulating endothelial progenitors involved in postnatal angiogenesis, inflammation and tissue regeneration[23,24]. Subsequently, it was identified in several human normal tissues and on CSC from a variety of solid tumors including brain, colon, liver, lung and prostate neoplasms[23,25].

Two studies first identified CD133 as a marker for stem cells in CRC. Ricci-Vitiani *et al*[16] showed the tumorigenic potential of CD133+ human CRC cells and evidenced their ability to engraft and give rise to visible tumors in immunodeficient mice even after serial transplantations. Simultaneously, O’ Brien *et al*[17] demonstrated an enrichment of more than 200-fold of cancer-initiating cells in the subsets of CD133+ cells isolated from human CRC samples compared to unsorted cancer cell populations. Moreover, they showed that liver metastases are enriched with a population of CD133+ cancer cells, a finding also confirmed by our group[26], and observed that tumor xenografts generated from CD133+ cells reproduced the histological features of the original tumor[17].

CD133 is concentrated in plasma membrane protrusions, containing lipid rafts, and more recently several studies have suggested a link between the release of CD133 contained in the membrane vesicles and cellular differentiation, proving that CD133 might play a key role in maintaining stem cell properties[27,28]. However, the discussion on the effective value of CD133 and its usefulness as a CSC biomarker is still controversial because other studies have shown that the CD133- population of CRC cells is also able to initiate tumor growth in immunodeficient mice[29]. More recently, Feng *et al*[30] proposed another possibility to explain the central issue of the debate, showing that the sorted CD133+ and CD133- SW620 colon cancer cells can undergo a conversion between the two cell subsets, this resulting in contradictory data. Moreover, Hsu *et al*[31], showed that the exposure to environmental stress, hypoxia and cell-adhesion free condition, promoted switching of SW620CD133- cells to SW620CD133+ cells while exposure to ECM components promoted switching of SW620CD133+ to SW620CD133- cells. The switching between the two subpopulations might be important for the adaptation to the microenvironment in tumor colonization (Figure 5).On this base, the current concept that CSCs unidirectionally differentiate into non stem cells could be challenged by the findings that non CSCs can convert in a stem-like state within the tumor depending on environmental stimuli[31].

Although the exact functional role of CD133 is still controversial, several studies have addressed its potential diagnostic and prognostic value as well as its intracellular signaling pathways. Several papers investigated the prognostic role of CD133 expression by immunohistochemistry and showed a high prognostic relevance for colon cancer progression and metastasis. Kojima *et al*[32] linked CD133 overexpression with a worse outcome and a higher risk of metastasis in CRC patients, a finding confirmed by Horst and others who showed that CD133 expression is an independent prognostic marker for overall survival[32,33]. Ong *et al*[34] demonstrated that high expression of CD133 is associated with resistance of CSC to 5-FU-based chemotherapy as well as with a significant worse survival. Moreover, CD133+ CSC cells have been shown to be more resistant to conventional radiation therapy, thus suggesting that post-chemoradiotherapy CD133 expression may predict the risk of distant recurrence and poor survival in radiotherapy-treated CRC patients[35].

Chao *et al*[36] proposed that CD133+ CRC cells are more tumorigenic than CD133- cells due to their interaction with carcinoma-associated fibroblasts in tumor microenvironment by the paracrine signaling axis CXCR4-SDF-1 (Figure 6). This evidence was confirmed by Zhang et al who showed that the co-expression of CXCR4 and CD133 on tumor cells was an independent risk factor for poor overall survival in stage II and III CRC patients[37]. The prognostic role of CD133 in CRC patients was confirmed by Kemper et al who showed a relationship between CD133 expression and the presence of mutations in K-Ras or B-Raf genes and suggested that CD133 might be regulated by the Ras-Raf-Mek-Erk pathway[38](Table 2).

The study of Mohammadi *et al*[39] was the first to evaluate the expression of CD133 in premalignant colorectal lesions such as non-dysplastic serrated polyps that comprise hyperplastic polyps (HP) and the non-dysplastic subset of sessile serrated adenoma-polyp-lesions (SSA/P/L) and its borderline variant. They showed that SSA/P/L and its borderline variant significantly express higher levels of CD133 than HP. They demonstrated that this premalignant colorectal lesion could be easily identified by determining the CD133 immunoprofile thus suggesting the usefulness of CD133 immunohistochemical evaluation in the diagnostic clinic routine[39]. Our group also reported that CD133 expression in human CRC is an independent risk factor associated with patient survival in multivariate analyses[40]. However, overall the data available in the literature do not allow a definitive and clear-cut assessment of the potential prognostic significance of CD133 expression which, as previously mentioned, is also the result of different antibodies, protocols and scoring criteria used for the evaluation of CD133 expression levels in clinical samples[41]. Therefore, some controversies could be a consequence of using different types of primary anti-CD133 antibodies to identify CD133+ cells: Most of the studies use the anti-human CD133/clone AC133 monoclonal antibody (Milteny) recognizing a glycosilated extracellular epitope of the CD133 molecule which can be downregulated independently from the corresponding mRNA and protein[28]. However, several other antibodies are available and are indistinctly used although they recognize different epitopes of the molecule and could give different results[41] (Figure 7).

The role of CD133 in colorectal tumorigenisis has been also investigate in mice. Zhu *et al*[42], demonstrated that in a murine model of colorectal tumorigenesis the endogenous activation of the Wnt signaling was associated with a marked expansion of CD133+ cells which replaced normal mucosa architecture giving rise to neoplastic lesions. Our group analyzed by immunohistochemistry the expression of CD133 in a mouse model of colitis-related colon tumorigenesis induced by a combined treatment with azoxymethane and dextran sodium sulphate. In normal tissues rare scattered positive cells were detectable at the bottom of the crypts. The percentage of positive cells significantly increased in dysplastic lesions and appeared to progressively decrease in the passage from dysplasia to adenoma and then to cancer although remaining constantly higher than in adjacent normal tissues[43]. Overall these data, considered together with Mohammadi findings, suggest that upregulation of CD133 expression likely occurs at early stages and contributes to the entire process of colon tumorigenesis[43,44].

The identification of the potential molecular pathways involved in the enhanced tumorigenicity associated with CD133 expression is of great interest since it could be useful to identify and develop a targeted anticancer therapy against the CSC population. It has been reported that the CD133 glycoprotein is phosphorylated on the tyrosine-828 and tyrosine-85 residues within its C-terminal cytoplasmic tail, in a Src kinase-dependent manner. The tyrosine-828, upon phosphorylation could serve as a binding site for the SH2 domains of tyrosine kinases[44]. The phosphorylation of tyrosine-852 does not require the binding to the SH2 domains. In this regard, Wei *et al*[45] showed that, in the glioma CSCs, the phosphorylation of the tyrosine 828 is involved in the binding to p85 (PI3K regulatory subunit) and in the subsequent activation of PI3K/Akt pathway, which, finally, promotes the self-renewal and tumor formation of CSCs (Figure 8). Wang *et al*[46] reported that the inactivation of Akt and Erk pathways prevented the preferential survival of CD133+ colon cancer cells isolated from primary CRC and decreased their tumorigenicity. Moreover, the downregulation of Akt and Erk by short interfering RNAs attenuated the colony formation ability of CD133+ cells[46]. More recently, it has been also showed that Silibinin, a chemo-preventive agent proved to be effective in several types of cancer, acts by inhibiting the PP2Ac/Akt/mTOR pathway which is associated with a reduction of CD133 expression in CRC spheroid cultures[47]. The Wnt signaling cascade plays various roles in stem cell maintenance, cell proliferation, differentiation and apoptosis and the deregulation of the Wnt pathway is associated with cancers. Corbo *et al*[48] reported a positive correlation among CD133 expression, Wnt pathway activation and increased SRp20 expression (splicing factor, a newly identified target gene of the Wnt/â- catenin pathway) in colon cancer cells. Furthermore, fibronectin, a major extracellular matrix glycoprotein, has been shown to be required for maintaining CD133 and CD44 positive subpopulations and tumorigenic capacity of CRC cells by activation of Wnt/â-catenin and its downstream integrin-Fak-Erk signaling pathways[49].

The regulation of CD133 expression is not fully understood but several evidences suggest the existence of multiple mechanisms involved in the regulation of CD133 expression and/or activity. As previously mentioned, CD133 is concentrated in plasma membrane protrusions and the release of CD133-containing membranous vesicles has been shown to contribute to the regulation of CD133 expression levels in several cell types[27]. Post translational modifications (*i.e.*, glycosylation) have been also suggested to play a role in the regulation of CD133 activity and its significance as a CSCs marker[28]. Indeed, it has been proposed that AC133, one of the most important epitopes of the molecule, rather than the entire molecule itself, might be important as CSCs marker.

Mak *et al*[50] proposed that CD133 expression is also regulated at a protein level by the deacetylase HDAC6, whose interaction with CD133 prevents its degradation by deacetylating á-tubulin and promotes the deacetylation of â-catenin and the activation of its signaling pathway. Moreover, they demonstrated that the inhibition of HDAC6 promotes CD133 trafficking into endosomes by increasing á-tubulin acetylation and is associated with â-catenin degradation (Figure 9).

The regulation of CD133 gene expression is also still poorly understood. Hypoxia and increased expression of hypoxia-inducible factors (HIFs) are associated with tumor progression and patient mortality in many solid tumors such as colorectal cancer, in which high expression levels of HIF-1α have been associated with poor prognosis[51]. Ohnishi *et al*[52] suggested that the activity of one of the putative CD133 promoters (P5) is regulated by HIFs in human embryonic kidney and colon cancer cells. In particular, the CD133 promoter P5 appears to be activated by HIF-1α and HIF-2α through one of two E-twenty six (ETS) binding sites. This finding is consistent with the observation of Mao *et al*[53] that the CD133+ populations in human CRC specimens express more HIF-1α than the CD133- cell population. Moreover, they engrafted human CRC specimens in BALB/c nu/nu mice and demonstrated that the majority of the CD133+ population in tumor xenografts was localized in the hypoxic region. The same Authors also demonstrated that the percentage of CD133+ cells increased following chemotherapy (5-fluorouracil, oxaliplatin or 5-fluorouracil plus oxaliplatin) thus indicating that CD133+ cells were less sensitive to drugs than the CD133- counterparts and that the tumor hypoxic region could be associated with chemotherapeutic resistance of colon CSCs[53]. The possibility that potential epigenetic mechanisms might be also involved in the regulation of CD133 expression in CRC has been suggested by Yi *et al*[54] who described an abnormal DNA hypermethylation in a CpG island in the promoter region of the CD133 gene in colon cancers cells but further studies are required to definitively address this type of regulation for CD133 expression.

All these findings suggest a potential key role of CD133 in the initiation and progression of human CRC and support its value as a possible prognostic and diagnostic marker in CRC. The knowledge of the regulatory mechanisms upstream of CD133 and of the molecular mechanisms activated downstream could be useful in the development of targeted drugs specifically directed against CSC, in an attempt to prevent recurrence, metastasis and chemotherapy resistance in CRC patients.

***CD44***

CD44 is member of a family of transmembrane proteins that include at least 20 variants resulting from a single gene by both alternative splicing and post-translation modifications[55]. The human CD44 gene includes 20 exons: exons 1-5 and exons 16-20 form a mRNA that code for a standard form of CD44 which is present in all tissues (CD44s); exons 6-15 are subject to alternative splicing that, in theory, may give life to more than 1000 variant isoforms of CD44 (CD44v)[56]. The standard isoform of human CD44 protein contains 363 amino acids and is formed by three regions: the extracellular (270 aa), the transmembrane (21 aa) and the C-terminal cytoplasmic (72 aa) domains. The presence of variable exons, mainly involving the extracellular domain, confers to CD44 a large variability of biological functions, that contributes to tumorigenicity when CD44 is expressed on tumor cells[56].

CD44 is a cell adhesion molecule that allows cell-cell and cell-ECM interactions through the binding to its principal ligand, hyaluronic acid (HA). It is also involved in lymph node homing and lymphocyte activation, myelopoiesis, lymphopoiesis, and angiogenesis[56]. CD44s, the smallest CD44 isoform that lacks variant exons, is abundantly expressed by both normal and cancers cells, whereas the CD44v isoforms that contain a variable number of exon insertions are mainly expressed by cancer cells[56].

CD44 is submitted to sequential proteolytic cleavages in the ectodomain and intramembranous domain, key events for the CD44 dependent cell-matrix interaction and signaling pathway. Cleavage of CD44 ectodomain is regulated by multiple stimuli such as extracellular Ca2+ influx, activation of protein kinase C or Ras and is mediated by membrane-associated matrix metalloproteinases (MMPs). The release of the soluble ectodomain (soluble CD44) regulates cell attachment and migration and induces the intramembranous domain cleavage, mediated by the presenilin (PS)-dependent ã-secretase, that release the intracellular domain of CD44 (CD44-ICD). CD44-ICD translocates to the nucleus, where it activates gene transcription, including CD44 itself, via binding to TPA-responsive elements[57] (Figure 10).

CD44 has been proposed as CSCs marker of several solid tumors, including breast, pancreas, head and neck, non-small cell lung, hepatocellular and colon cancers[18,56]. CD44+ CRC cells display a greater ability to form colonies *in vitro* and a higher tumorigenicity *in vivo* compared to CD44- cells. Moreover, only CD44+, but not CD44- CRC cells are able to retain the morphological and phenotypic characteristics of tumor lesions from which they were derived following serial transplantations[58].The association of CD44with CD54(a member of the immunoglobulinsuper-family also called intercellular adhesion molecule-1) has been shown to specifically identify rectal CSC displaying the ability to self-renew *in vivo* and *in vitro*, form spheres and recapitulate tumor bulk[59].

CD44 expression is regulated by the Wnt signaling pathway *via* â-catenin. In fact, activation of â-catenin/Tcf-4 signaling in intestinal tumors is associated with CD44 overexpression and deletion of CD44 in APC Min/+mice inhibits the initiation of tumors[60]. CD44 appears to be essential for stemness maintenance of colorectal CSCs since it is involved in the activation of the tyrosine kinase receptor c-Met[58]; CD166, a mesenchymal stem cell marker (see below), has been suggested as a potential Co-CSCs marker, together with CD44, in human CRC, since in xenograft CD44+/CD166+ cells have a higher tumorigenicity as compared to CD44+CD166- cells. The surface phenotype EpCAMhigh/ CD44+/ CD166+ has been proposed as an alternative to the CD133 positivity for the selection of colon CSCs[18] and CD44+ CRC cells have been shown to display a higher proliferation, more robust formation of colonies, less spontaneous apoptosis and a higher resistance to drug-induced cell death compared to CD44- cells[47].

More controversial are the findings regarding the role of CD44 in tumor progression and in the development of metastases in CRC. Several studies showed that expression of CD44 on tumor cells is correlated with tumor progression and metastasis while others have suggested an inverse correlation or no correlation at all[57,58].

Down-regulation of CD44 was initially related to a decrease in the metastatic potential of CRC cells[61], while more recently Dallas reported that down-regulation of CD44 leads to an increase of the metastatic and migratory potential of CRC cells[62]. It was observed that high-grade CRC have higher CD44 expression levels compared to low-grade tumors and this over-expression was associated with a reduced patients survival[63]. On the other hand, Ylagan *et al*[64] reported that the loss, rather than an increased expression, of CD44 is associated with an increased tumor aggressiveness while Fernández *et al*[65] demonstrated that CD44 expression levels were related to proliferation in CRC, but not with patients outcome. Subsequently, CD44 expression in human CRC was associated with the depth of invasion and lymph node involvement, and CD44s overexpression was suggested to be an independent unfavorable prognostic factor for overall survival in advanced CRC[66]. These findings were not confirmed by Lugli *et al*[67] who reported that the loss of CD44 is associated with more advanced tumor stage, the presence of vascular invasion, lymph node involvement and an infiltrating tumor border. Patients with tumors displaying a loss of CD44 or CD166 expression in the invasive front of the lesion had an adverse outcome compared with those expressing at least one of the two markers[67] (Table 3).

Further studies are warranted to further understand the suitability of CD44 molecule as a CSC marker in CRC and its role in human colorectal tumorigenesis.

***EpCAM***

Epithelial cell adhesion molecule (EpCAM), initially described in 1979 as a tumor associated antigen in human CRC[68], is a 30-40 kDa transmembrane glycoprotein showing frequent and high-level expression in a variety of human epithelial normal and cancer tissues, including colon[69]. It has been also detected on normal stem and progenitor cells and in cancer-initiating cells isolated from colon, breast, pancreas and prostate carcinomas[16,17,70]. Several evidences demonstrate that EpCAM is involved in cell adhesion, proliferation, differentiation and migration as well as in cancer and stem cells signaling[71,72].

The human EpCAM protein was independently identified by various research groups and, for this reason, several terms have been used to identify the molecule on the basis of the monoclonal antibody used to identify it[70]. However, it has been lately agreed the use of the term “EpCAM”, without other specifications[70].

EpCAM displays a marked expression gradient from crypts to the apex of villi in normal colon tissue: adenoma development is associated with an increased EpCAM expression, and EpCAM overexpression is frequently observed in colorectal carcinoma[73]. Denzel *et al*[72] demonstrated that EpCAM is less accessible to antibodies in colon adenomas than in cancer because, in the last condition, EpCAM is activated by proteolysis in EpICD, the intracellular domain of EpCAM, and is intracellularly redistributed in dispersed patterns. They also showed that EpICD translocates into the cytoplasm together with the scaffold protein FHL2 and joins to the transcriptional regulator â-catenin to form a complex which, within the nucleus, interacts with Lef and binds to DNA inducing c‑myc, cyclin A and cyclin E expression[72] (Figure 11). These findings were further confirmed by the observation that nuclear and cytoplasmic EpICD in solid epithelial cancers, such as colon, are increased, while the expression of membrane EpEx, the extracellular domain of EPCAM, is absent or reduced[74].

EpCAM was initially identified as a marker of human colorectal CSCs by Dalerba *et al*[18] who focused on two markers previously identified on human breast CSC: CD44 and EpCAM. Two main populations of epithelial cells were sorted from primary human CRCs by FACS: EpCAMhigh/CD44+ and EpCAMlow/CD44- and their tumorigenic properties were assessed. The results obtained demonstrated that the injection of 200 to 500 EpCAMhigh/CD44+ cells in NOD/SCID mice were sufficient to give rise to a tumor, whereas up to 104EpCAMlow/CD44- cells failed to form visible tumors. The xenograft tumors from EpCAMhigh/CD44+ reproduced the histopathology and phenotypic heterogeneity of the original tumors including the presence of variable percentages of both EpCAMhigh/CD44+ and EpCAMlow/CD44- cell populations[18]. They also verified that human EpCAMhigh/CD44+ cells from xenogenic colorectal tumors can be further stratified on the basis of the expression of the protein surface marker CD166, which could be used for the enrichment of colorectal CSCs[18]. Similar conclusions were also reached by Dylla *et al*[75] who suggested that one of the possible reasons of CRC resistance to chemotherapeutic agents might be at least in part attributed to the presence of EpCAM+/CD44+ CSC since residual tumors after chemotherapy are enriched of these cells.

All these findings about EpCAM signaling and its involvement in various cellular processes, provide a strong basis for further studies to better understand its potential clinical, prognostic and therapeutic value in CRC patients.

***CD24***

CD24 is a small, heavily glycosylated mucin-like adhesion molecule consisting of 27 amino acids with several potential O- or N-linked glycosylation sites, which lead to a molecular mass ranging between 38 and 70 kDa[76]. CD24 is attached to cell membranes by a phosphatidylinositol anchor and is expressed physiologically in the developing pancreas and brain and in pre-B lymphocytes, in regenerating muscle, in normal keratinocytes and in renal tubules[76]. It is physiologically localized in lipid rafts where it seems to be involved in the regulation of cell adhesion and signaling[76].

CD24 is expressed in various hematologic malignancies and solid tumors such as neuroblastoma, rhabdomyosarcoma, renal cell carcinoma, breast, ovarian, prostate, lung, colorectal and gastric cancer[76,77]. The observations that CD24 is one of the possible ligands of P-selectin and one of the adhesion receptors expressed by activated endothelial cells and platelets suggest that this molecule might play a role in the process of cancer metastasis[76].

Nestl *et al*[77] initially reported an increased expression of CD24 RNA in CRC: they showed that CD24 mRNA was weakly detectable in normal colonic mucosa but highly expressed in tumor cells, and to a lesser extent in the surrounding stroma. Later, Weichert *et al*[78] analyzed CD24 protein expression in colon cancer cell lines and human CRC and correlated it to clinic-pathological variables including patient survival. From this study emerged that the majority of CRCs showed both membranous and cytoplasmic CD24 staining, and that the membranous CD24 staining was associated with metastasis but was not significantly related to other clinic-pathological variables, while the cytoplasmic staining could be considered an independent prognostic marker related with a poor patient survival[78]. Conversely, Sagiv *et al*[19] failed to demonstrate any prognostic significance of CD24 expression level in CRC: in their study CD24 was similarly highly expressed in both adenomas and carcinomas. Moreover, unlike Weichert findings, they only reported a membranous staining. The same study also showed that CD24 is expressed early in the multistep process of CRC carcinogenesis, a finding consistent with its potential role as CSC marker.

Contradictory data have been reported in the literature concerning the prognostic value of CD24 whose expression levels have been reported to be not related with survival of CRC patients despite their significant relationship with conventional clinic-pathological factors such as tumor invasiveness and degree of differentiation[79]. Therefore, the real prognostic role of CD24 in CRC remains still unclear and controversial and it should be better elucidated by further studies.

Spheroid cultures of primary CRC have tumor-initiating capacity and are capable of inducing tumors upon xenotransplantation. These tumors resemble the original neoplasms both from a morphological point of view and the expression of specific markers[16]. Vermeulen *et al*[14] suggested that the co-expression of CD133 and CD24 could improve the identification of the clonogenic population within the spheroid cultures, and that both markers are downregulated during cell differentiation. CD24 was also used, in association with CD44, to identify and characterize CSCs from CRC cell lines by Yeung *et al*[80]. They demonstrated that the CD44+/CD24+ subpopulation of cells, isolated using FACS sorting, was the most clonogenic, giving rise to the highest proportion of megacolonies (complex structures resembling colonic crypts) compared to CD44-/CD24- cells. CD24+ subpopulation was also shown to exhibit cancer stem-like properties such as enhanced chemotherapy-resistance, self-renewal and tumorigenic capacity both *in vitro* and *in vivo*, compared to CD24- subpopulation isolated from CRC cell lines[80].

To our knowledge only few studies have investigated the underlying molecular mechanisms and the exact role played by this cell surface marker in CRC tumorigenesis. Thus, CD24 has been shown to activate Erk1/2 and p38 MAPKs and to increase the activity of Src and induce miR-21 expression, which in turn inhibits the expression of Pdcd4 and PTEN. On the other hand, the expression of CD24 and Src appears to be suppressed by miR34a through the downregulation of miR21[81].

Further studies are warranted to clarify the real activity of CD24 in CSCs and the key regulatory molecular networks involved in its role in colorectal tumorigenesis.

***CD29***

CD29 (â1-integrin) is a member of the integrin family and consists of a large extracellular domain, a single transmembrane stretch and a short cytoplasmic domain. It acts as a receptor for extracellular matrix proteins and activates signaling molecules and pathways that regulate cell migration, proliferation, survival, differentiation and death[82].

In fact, CD29, by binding with fibronectin or Type I collagen, allows activation of Fak by Src leading to the activation of Erk that regulates cell proliferation. Erk, through phosphorylation of myosin light chain (MLC) by MLC kinase, also regulates cytoskeleton reorganization and cell motility. Moreover, CD29 regulates cell survival through the activation of Akt pathway[83].

CD29 has been initially described as an epidermal stem cell marker, and subsequently as a regulator of spermatogonial stem cells homing and of hematopoietic stem cells[22]. In normal human colon, CD29 is expressed at the bottom of the crypts, where it identifies a cell population that is capable of forming colonies in agar. For this reason, CD29 has been proposed as a stem/progenitor cell marker[27] and as a marker of colon CSC. In fact, it has been shown that CD133+CD29+ colon CSC are biologically characterized by self-renewal, proliferation and differentiation[14,20].

CD29, with E-cadherin, mediates cell-cell and cell-collagen interactions that are required for the maintenance of the differentiated phenotype of human CRC cells. Thus, CD29 downregulation may be responsible of the switch from differentiated to undifferentiated phenotype *in vivo*[84]. CD29 seems to be also implicated in the enhancement of the metastatic activity of CRC cells. In fact, Okazaki *et al*[85] showed that CD29 was significantly increased *in vivo* in metastases derived from human CRC cells. CD29 expression appears also to increase in the passage from adenoma to adenocarcinoma and with increasing tumor stage[86].

CD29 expression may be also associated with overall survival in CRC patients. In fact, loss of CD29 expression is associated with advanced stage and with poor prognosis and CD29 expression decreases in metastatic lesions[87], although other Authors have suggested that CD29, in combination with CD49b, might contribute to the acquisition of a metastatic potential in CRC cells. Finally, CD29 expression has been shown to identify the population of CRC cells that are more resistant to radio and chemo-therapy[88]. Further studies are needed to understand the specific role of CD29 as CSC marker as well as in the progression of CRC.

***Lgr5***

Lgr5, (Leucine-rich repeat-contaning G protein-coupled receptor 5) also known as Gpr49, is an orphan G protein coupled receptor, characterized by a large leucine-rich extracellular domain and seven transmembrane domains. It is a receptor for R-spondin proteins which represent secreted agonists of the canonical Wnt/â-catenin signaling pathway[89,90].

Lgr5 is a member of the glycoprotein hormone receptor subfamily that includes the thyroid-stimulating (TSH), the follicle-stimulating (FSH) and the luteinizing (LH) hormones receptors[21].

Lgr5 was first identified in human colon cancer cell lines harboring Wnt activating mutations as a Wnt target gene[4,91] and was then shown to be overexpressed in other human malignancies such as ovarian, hepatocellular, esophageal and basal cell carcinomas[92].

Since Lgr5 is one of Wnt target genes, it is not surprising that this protein is found expressed in different stem cells[5,93]. In the intestine Lgr5 is expressed in mature intestinal stem cells at the bottom crypt[4,5]; more specifically, Barker *et al*[4], using in situ hybridization demonstrated that Lgr5 is selectively expressed on few proliferating cells alternated with Paneth cells at the bottom of the crypts in the small intestine. These cells, known as crypt base columnar cells, are cycling cells and represent intestinal stem cells. These findings have suggested that Lgr5 could have an important role in colorectal carcinogenesis and that it could be an ideal marker of colorectal CSC.

Several research groups have investigated whether Lgr5 could play a role in colorectal tumorigenesis and several studies suggested that there is a close correlation between Lgr5 expression and colon cancer progression[90,92].

In fact, Lgr5, which is normally localized to the basal intestinal crypt area, is expressed only in the peripheral region of adenomas and ubiquitously in established adenocarcinomas. It has been hypothesized that the accumulation of genome mutations occurring during the process of malignant transformation, might lead to loss of Lgr5+ cells polarity that can thus migrate to the tumor-host interface (carcinoma in situ) and then in all the tumor (advanced cancer)[94]. The selective expression of Lgr5 in the peripheral region of adenomas supports the hypothesis that it might mark intestinal CSCs. In favor of this hypothesis is the work of Batlle *et al*[95] that have reported that Lgr5 is selectively expressed on human colon CSCs. This finding has been further confirmed by Kemper who demonstrated that Lgr5 identifies the CSC fraction in CRC and that it is expressed at high levels in spheroid cultures derived from primary CRC (that are known to be enriched for CSCs) and decreased following cellular differentiation[38].

Since Lgr5 is expressed at high levels in both colorectal adenomas and adenocarcinomas it likely plays an important role not only in the early but also in the late events of tumorigenesis, such as invasion and metastasis. Moreover, high Lgr5 expression has been shown to correlate with mesenchymal characteristics of tumors, such as high expression of vimentin and low expression of miR-200c, and with increased invasiveness and lymph node metastases[92,94].

Overall, the available evidence suggests that Lgr5 could play a key role in the development and progression of CRC and might represent a useful marker to identify and/or target CSC in colon cancer.

***CD166***

Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a member of a subgroup of transmembrane glycoproteins in the immunoglobulin superfamily, characterized by the presence of five extracellular immunoglobulin-like domains (VVC2C2C2)[96].

CD166 is able to form low-affinity hemophilic interactions and much stronger heterophilic interactions with CD6 expressed on T lymphocytes, thymocytes and on a subset of B cells[97].

Beside hematopoietic cells, expression of CD166 has been reported in a wide variety of tissues and cells including selected epithelia, lymphoid and myeloid cells, fibroblasts, neurons, hepatocytes, pancreas acinar and islet cells[98]. CD166 is also present in a large number of tumors including breast, lung, colon and prostate cancer and melanoma[98].

In the small intestine and in the colon, CD166 was observed at high levels on the surface of cells within the stem cell niche at the base of the crypt, but little is known about its endogenous function. However, CD166 seems to be involved in the morphogenesis of tubular structures by cell-cell and cell-matrix interactions[99].

Expression of CD166 in colon cancer has been analyzed by several groups with conflicting results. Weichert *et al*[100] suggested that CD166 up-regulation is an early event in colon tumorigenesis because it was found in all adenomas of the colon. Moreover, they reported by immunohistochemistry both a cytoplasmic and membranous staining for CD166 in CRC and a correlation between high membranous CD166 expression and poor prognosis. On the contrary, Horst and collaborators did not find any correlation between CD166 expression and CRC patients outcome[101].

The study conducted by Lugli revealed an association between the loss of CD166 and an increase in tumor size, lymph node metastasis, tumor infiltration and a shorter overall survival[67].

These findings have been partially confirmed by a recent work showing that CD166 expression is a positive prognostic marker for overall survival in CRC patients. CD166 expression in well differentiated CRC suggests a role of the protein in the early stages of tumorigenesis and, since CD166 seems to be involved in cell-cell and cell-matrix adhesion, its loss may be associated with reduced cell adhesion and therefore with a higher metastatic potential of tumors[102].

It has been recently suggested that CD166 may contribute to the identification of colorectal CSCs[18] but its role in CRC tumorigenesis as well as a marker of CSC remains to be defined.

**THERAPEUTICS RELEVANCE OF COLORECTAL CANCER STEM CELLS**

Cancer stem cells are believed to be resistant to chemo- and radiation-therapy and are indicated to be the cause of cancer relapse and metastasis: conventional anticancer therapy wipes out the bulk populations but the surviving CSCs repopulate the tumor (Figure 3). Therefore, targeting both CSC and the bulk populations is essential for complete tumor eradication. Thus, the identification of colorectal CSC markers and their signaling pathway is crucial for the development of novel therapies which could specifically target these cells.

The potential therapeutic strategies aimed at selectively target CSCs, which are beginning to be experimentally validated, include the elimination of CSCs through agents which target specific markers of CSC (such as monoclonal antibodies) or interfere with CSC-specific pathways[103].

Todaro *et al*[104] demonstrated that CD133+ colon CSC produce and use the cytokine IL-4 to protect themselves from apoptosis caused by conventional chemotherapy agents, 5-fluorouracil and oxaliplatin. In fact, the simultaneous treatment with antibodies to IL-4 greatly increased the antitumoral cytotoxic activity of the drugs.

It has been also reported that a 5-fluorouracil and oxaliplatin chemoresistant derivative of the HT29 human CRC cell line displayed an enrichment of CD133+ and CD44+ cells with an increased expression of the Type 1 insulin-like growth factor receptor (IGF-IR). Treatment with a monoclonal antibody to IGF-IR induced a significant inhibition of tumor growth, thus demonstrating an enhanced sensitivity of colon CSC to IGF-IR specific targeted therapy[105].

More recently, Bach *et al*[106] used measles viruses, oncolytically active against various types of human cancer, to generate CD133-specific measles viruses (MV) and to provide a new CSC-specific anticancer therapy. They were able to efficiently infect the primary colonspheres to test the oncolytic activity of CD133-MV on colon primary tumor cells. The infection caused a rapid loss of CD133+ cells and, when implanted in NSG mice, the CD133-MV infected tumor spheres formed tumors smaller than uninfected tumor spheres. However, no effect in term of tumor volume was observed when the resected tumors were transplanted in secondary mice and the re-isolated tumors contained 70% of CD133+ cells[106].

Given that CD133 is also expressed on normal stem cells, Bostad *et al*[107] have developed a site-specific strategy that allows to release the drug only in the tumor area. They developed an immunotoxin targeting CD133 by using the photochemical internalization (PCI) technology. The biotinylated anti-CD133 antibodies were mixed with streptavidin-saporin (sap) to form the model of anti-CD133-sap immunotoxin. Saporin, a plant toxin, is a potent ribosome inactivating protein (RIP) and was used as the toxin component of the immunotoxin. The aim of this technology was to avoid the degradation of the drug by the lysosomes before the drug has interacted with its biological target, and the main advantage should be the accumulation of the photosensitizer preferably in the neoplastic tissue. This report demonstrated that the CD133high population of WiDr colon cancer cells is more resistant to photodynamic therapy (PDT) than the CD133low population but the PCI of a CD133-targeting toxin is able to sensitize and destroy these resistant cells. Thus, PCI-based anti-CSC strategy could be a specific method for a selective killing of CD133+ CSCs while sparing normal stem cells[107]. Chen *et al*[108] tested the effects of CD133 monoclonal antibody (Miltenyi) on hepatocarcinoma cells. The CD133 monoclonal antibody treatment, under extracellular low glucose condition, inhibited the proliferation of hepatocarcinoma cells, suppressed spheroid and colony formation, attenuated xenograft tumors and improved the efficiency of chemotherapy. Moreover, Swaminhatan and others developed nanoparticles formulated using the biodegradable poly (D, Llactide- co-glycolide) polymer and surface functionalized with an anti-CD133 antibody (CD133NPs). The CD133NPs were loaded with paclitaxel and were able to reduce the fraction of tumor-initiating cells *in vitro* and tumor recurrence in the MDA-MB-231 xenograft tumor model[109].

EpCAM has been also suggested as a potential target for the development of a CSC-specific therapy for CRC. Several clinical trials have already evaluated the efficacy of a monoclonal antibody to EpCAM for a targeted treatment of CRC. Edrecolomab, a murine monoclonal anti-EpCAM antibody, was the first immunotherapeutic agent licensed for the use in a large-scale human anti-tumor immunotherapy trial. In 1994, Riethmüller *et al*[110] randomly assigned to adjuvant therapy with Edrecolomab a series of patients with a resected Dukes’ C CRC: they showed an improved survival rate, and a reduction of mortality and disease recurrence[110,111]. These promising results were not further confirmed. In fact, Punt *et al*[111] showed that the addition of Edrecolomab to fluorouracil and folinic acid in the adjuvant treatment of resected stage III CRC did not provide any further improvement in term of survival, and that the immunotherapy alone was associated with a significant shorter disease-free survival[111]. Similar findings have been reported by Fields *et al*[112] who adopted a combination of fluorouracil-based therapy and Edrecolomab for the treatment of stage III colon cancer patients, getting poor results.

More recently, Waldron *et al*[113] have characterized a biospecific target toxin, which is composed by anti-EpCAM and anti-CD133 scFv (single-chain variable fragment), and have focused on three different types of carcinoma: head and neck, breast, and colon carcinoma. The toxin, called deimmunized CD133KDEL (dCD133KDEL), was synthesized using an anti-CD133 scFv that recognized the loop two of the extracellular domain of CD133 and both the glycosylated and unglycosylated forms of CD133. The anti-CD133 scFv was fused with an anti-EpCAMscFv and with a truncated form of Pseudomonas exotossin A (PE38) and the construct called dEpCAMCD133KDEL and showed a strong inhibition of proliferation in CRC cell lines.

CD44 can represent a suitable therapeutic target for CRC, since it presents two distinct forms between normal and cancer cells. In fact, the different local environmental pressures are responsible for different splicing and post-translational modifications which give rise to different CD44 molecules that can be recognized by specific agents useful for both diagnosis and therapy[114].

CD44 knockdown was shown to inhibit tumor growth and metastasis *in vivo*[61], a finding confirmed by Du *et al*[58] who used lentiviral RNA interference to stably knock down CD44 or CD133 in CRC primary cells isolated from patients. These Authors reported that knockdown of CD44 reduced clonal formation, whereas CD133 knockdown had little effect compared to control.

The combination of curcumin and dasatinib has been also suggested as a therapeutic strategy for chemo-resistant CRC. In fact, the combination therapy with curcumin and dasatinib inhibited the growth of chemo-resistant HT29 and HCT-116 CRC cells, the formation of colonospheres and extracellular invasion. The expression of CSC markers CD133, CD44, CD166 and ALDH1 displayed a 25%-30% decrease in cells treated with curcumin and dasatinib thus suggesting that the combination may be used as a specific CSC targeted therapy to prevent recurrence of CRC[115].

Another study demostrated that difluorinated-curcumin (CDF) in combination with 5-fluorouracil and oxaliplatin, the standard of CRC chemotherapy, was more potent than curcumin in reducing CD44 and CD166 expression in chemo-resistant CRC cells. This effect was associated with growth inhibition, induction of apoptosis and disintegration of colonospheres[116].

Misra *et al*[114] demonstrated that CD44v6 knockdown reduced the ability of CRC cells to signal through hyaluronan-CD44v6. They encapsulated plasmidic DNA coding CD44v6 shRNA into transferrin (Tf)coated nanoparticles which are recognized by Tf-receptor (TF-R) present at high level on tumor cells which then internalize the particles by receptor-mediated endocytosis. These nanoparticles were delivered within pre-neoplastic and neoplastic colon tissues in the Apc Min/mice model, causing inhibition of the CD44v6 expression. This inhibition was associated with a reduced adenoma number and growth through a hyaluronan/CD44v6/ErB2/Cox 2 interaction pathway[114].

Mesoporous silica nanoparticles (MSNs) have been proposed as nanocarriers for several anticancer treatments. Yu *et al*[117] have developed a targeted drug delivery system based on hyaluronic acid (HA) modified MSNs (HA-MSNs). HA-MSNs have a specific affinity to CD44 overexpressed on CRC cells and can enter cells *via* the HA receptor mediated endocytosis pathway. Doxorubicin (Dox), an anticancer drug, has been encapsulated into MSNs with or without HA. HCT-116 cells were treated with free Dox, Dox-HA-MSNs or Dox-MSNs. The cells treated with Dox-HA-MSNs presented a stronger inhibition of proliferation (51%) compared to the other two groups[117].

A new potential therapeutic approach targeting CSCs was suggested by Sagiv *et al*[118] who showed that the growth of human CRC cells lines, expressing the presumptive CSC marker CD24, was inhibited after treatment with three different anti-CD24 monoclonal antibody which showed a synergistic effect with chemotherapeutic agents[19,118].

Downregulation of CD29 expression by antisense oligonucleotide in the HT-29 human CRC cell line reduced both tumor cells migration *in vitro* and hepatic metastasis *in vivo*[37]. Interestingly, barberine, a botanical alkaloid with cytotoxic effects on most type of cancer cells, can inhibit the migration of SW480 and HCT116 CRC cells through a decrease of CD29 expression level *via* AMP-activated protein kinase thus suggesting the possibility to use this drug to specifically target CD29-expressing CSCs[119].

Targeting of CSC can be also obtained by interfering with the pathways involved in stemness maintenance such as Wnt, Hedgehog and Notch. Several approaches for CRC therapy have focused on Wnt pathway inhibition. Wnt family proteins are secreted intercellular signaling molecules that act as ligands to activate a specific signal transduction pathway. Upon binding of Wnt to its receptor Frizzled (FZD), the protein Disheveled (Dvl/Dsh) is activated and inhibits the Glycogen synthase kinase 3 (GSK-3) activity. The latter binds to axin, APC and Casein Kinase 1 (CK1), and forms a complex that binds â-catenin and promotes its degradation. When Wnt signaling inhibits GSK-3, â-catenin dissociates from the complex and enters the nucleus, where it binds to the DNA binding protein Tcf/Lef, becoming a transcription factor[120]. Efforts have been mainly devoted to the identification of small molecules inhibiting this pathway.

Chen *et al*[121], in a screen of a synthetic chemical library, identified a new small molecule able to inhibit the Wnt signaling. This compound, called IWP (inhibitor of Wnt production), inhibits the activity of Porcupine, a membrane-bound acetyltransferase, essential for Wnt production[121]. Similarly, using report-based screening approaches, Huang *et al*[122] found a small molecule, XAV939, that inhibits Wnt through the tankyrase inhibition, an event leading to an increase in the stability of axin and subsequent â-catenin degradation[122].

Pyrvinium, another small molecule promoting the degradation of â-catenin was identified by Thorne *et al*[123]. This molecule, promotes â-catenin phosphorylation through casein kinase activation. It was shown that pyrvinium treatment of CRC cells bearing APC or â-catenin mutation inhibits both Wnt signaling and proliferation[123].

Several studies have focused on the identification of molecules capable of destroying the interaction between Tcf/Lef and â-catenin and therefore of inhibiting â-catenin-dependent transcription. Three of these compounds were shown to inhibit CRC cells growth both *in vitro* and *in vivo*[124].

Emami *et al*[125] developed a compound, ICG-001, which specifically inhibited a co-activator essential for Wnt pathway activation. Treatment of CRC cell lines bearing APC or â-catenin mutations with ICG-001 induced cell death in a dose-dependent fashion while not affecting normal epithelial cells. An analogue of this compound was recently approved for phase I clinical testing[126].

The Wnt pathway has been also successfully inhibited using a specific anti-Wnt monoclonal antibody, which inhibits the proliferation and induces apoptosis in CRC cells, even in those with downstream mutations[127]. Numerous groups have tried to inhibit the Wnt pathway by inhibiting the FZD receptor activity.

A member of FZD family, FZD7, results predominantly expressed in CRC cells and it is implicated in canonical Wnt signaling in cells with APC or CTNNB1 mutations. The use of specific siRNA to knockdown the expression of endogenous FZD7 has proved effective in reducing the metastatic potential of CRC cells[128]. Similar effects have been obtained using an antibody targeting FZD7[129]. Remarkable results have been also obtained using inhibitors of Delta-like ligand 4 (DLL4), an important component of the Notch pathway. Human CRC xenografts treated with an anti-DLL4 antibody in combination with irinotecan have showed a reduction of CSCs and of tumor growth whereas treatment with irinotecan alone increased the percentage of CSCs[130,131].

**CONCLUSION**

The CSC model of tumorigenesis postulates that tumors are not cellularly homogenous but display a hierarchical structure and contain a rare population of cells, the CSC, that display the same self-renewal and proliferative potentials as normal stem cells associated with the capacity to give rise to tumors (Figure 2). As previously described, mounting evidence suggests the existence of a CSC population in human CRC[16,17].

It has been hypothesized that CSC may derive from transformation of quiescent, normal long-term stem cells or could result from the de-differentiation of more mature cells[15,16,17]. In CRC, the first hypothesis is supported by the observation that normal and cancer stem cells share similar properties and surface markers (*i.e.*, CD133 and Lgr5). However, it cannot be excluded that CSC might derive from cells that, at some specific stages of differentiation, undergo malignant transformation acquiring new properties including stem-like features. This hypothesis might explain the different aggressiveness of tumors which might relate to the different differentiation degree of cells undergoing the transformation event(s) as evidenced by the different tumor grading[15] (Figure 12).

The ability to identify and isolate CSC is essential to fully characterize them and to understand the molecular mechanisms responsible for their establishment and their maintenance. As mentioned, several approaches have been used to identify and isolate CSC the most important being the antibody-based technologies targeting CSC-specific surface markers. However, different antibodies, techniques and protocols are used in different studies and these certainly contribute to the conflicting results present in the literature. Thus, it will be important to define standardized procedures and reagents to identify CSC in clinical samples. Moreover, several questions remain unresolved especially regarding the significance of CSC markers and whether they play a direct role in essential CSC properties such as self-renewal and tumor-initiation ability or they are just markers of stem-like cells with no relevant physiological functions[44]. This is a very important issue in view of the possibility to develop specific anti-CSC therapies.

Indeed, the CSC model of tumorigenesis implies that targeting of CSC is essential for a complete eradication of the disease (Figure 3). This consideration fits well with the disappointing daily experience of oncologists facing occasional complete responses that do not translate into cure for patients. Indeed, the model hypothesizes that CSC must be completely eliminated in order to eradicate the disease and prevent recurrences/metastases. However, CSC have been reported to be relatively resistant to standard anticancer therapies, such as radiation and chemotherapy, which target rapidly proliferating cells[103].

Thus, initial responses to treatment could represent therapeutic effectiveness against the bulk cancer cells while sparing rare quiescent CSC which would then be responsible for tumor re-growth both at primary and metastatic sites. According to this model, a better understanding of the biology of CSC is essential to improve efficacy of anticancer therapies and several groups are pioneering the possibility of specifically targeting CSC through multiple approaches, as previously described[107,117,123]. A big issue will be the identification of substantial differences between normal and cancer stem cells and/or specific therapeutic strategies that would allow the development of drugs specifically targeting CSC while sparing normal counterparts. From this perspective, another important point to keep in mind is that standard response parameters might not be suitable to evaluate specific CSC-targeting therapies. Indeed, current evaluation criteria only take in consideration the effects of treatment on tumor bulk and thus might underestimate the effect of a therapy specifically targeting a rare population of cells within tumor mass. Thus, it will likely be important to re-examine the standard criteria to evaluate response therapy and other approaches, such as new CSC-specific imaging techniques, might be needed to this aim. This does not mean that conventional therapies will no longer have a place in the future anti-cancer protocols despite the fact that CSC may be resistant to them. Indeed, it seems realistic to anticipate that a useful approach to improve current treatment of solid tumors, including CRC, will be the combination of a specific anti-CSC treatment with traditional agents (*i.e.*, 5-fluorouracil and/or oxaliplatin) that can debulk the mass of cancer cells.

In conclusion, the CSC model of tumorigenesis has the potential to radically revolutionize the way how we look at malignant diseases as well as the clinical management of CRC patients. To this aim, it will be essential a definitive assessment of the roles that putative CSCs play in the development of human CRC and in specific aspects of malignancy. The ultimate proof of the relevance of CSCs in tumor development and in the clinical management of CRC cancer patients will be the demonstration that specific targeting of CSCs can improve patients outcomes, a goal strongly awaited by scientists, oncologists and, especially, patients.

**REFERENCES**

1. **Ferlay J**, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* 2013; **49**: 1374-1403 [PMID: 23485231 DOI: 10.1016/j.ejca.2012.12.027]
2. **McDonald SA**, Preston SL, Lovell MJ, Wright NA, Jankowski JA. Mechanisms of disease: from stem cells to colorectal cancer. *Nat Clin Pract Gastroenterol Hepatol* 2006; **3**: 267-274 [PMID: 16673006 DOI: 10.1038/ncpgasthep0473]
3. **Blanpain C**, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. *Cell* 2007; **128**: 445-458 [PMID: 17289566 DOI: 10.1016/j.cell.2007.01.014]
4. **Barker N**, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007; **449**: 1003-1007 [PMID: 17934449 DOI: 10.1038/nature06196]
5. **Sangiorgi E**, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. *Nat Genet* 2008; **40**: 915-920 [PMID: 18536716 DOI: 10.1038/ng.165]
6. **Moore KA**, Lemischka IR. Stem cells and their niches. *Science* 2006; **311**: 1880-1885 [PMID: 16574858 DOI: 10.1126/science.1110542]
7. **Medema JP**, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. *Nature* 2011; **474**: 318-326 [PMID: 21677748 DOI: 10.1038/nature10212]
8. **Fearon ER**, Vogelstein B. A genetic model for colorectal cancer tumorigenesis. *Cell* 1990; **61**: 759-767 [PMID: 2188735 DOI: 10.1016/0092-8674(90)90186-I]
9. **Pinto D**, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. *Genes Dev* 2003; **17**: 1709–1713 [PMID: 12865297 DOI: 10.1101/gad.267103Genes]
10. **Korinek V**, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. *Science* 1997; **275**: 1784-1787 [PMID: 9065401 DOI: 10.1126/science.275.5307.1784]
11. **Haramis AP**, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, Clevers H. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. *Science* 2004; **303**: 1684–1686 [PMID: 15017003 DOI: 10.1126/science.1093587]
12. **He XC**, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, Mishina Y, Li L. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. *Nat Genet* 2004; **36**: 1117-1121 [PMID: 15378062 DOI: 10.1038/ng1430]
13. **Dexter DL**, Spremulli EN, Fligiel Z, Barbosa JA, Vogel R, VanVoorhees A, Calabresi P. Heterogeneity of cancer cells from a single human colon carcinoma. *Am J Med* 1981; **71**: 949-956 [PMID: 7315857 DOI: [10.1016/0002-9343(81)90312-0](http://dx.doi.org/10.1016/0002-9343%2881%2990312-0)]
14. **Vermeulen L**, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. *Proc Natl Acad Sci USA* 2008; **105**: 13427–13432 [PMID: 18765800 DOI: 10.1073/pnas.0805706105]
15. **Gangemi R**, Paleari L, Orengo AM, Cesario A, Chessa L, Ferrini S, Russo P. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. *Curr* *Med Chem* 2009; **16**: 1688-1703 [PMID: 19442140 DOI: [10.2174/092986709788186147](http://dx.doi.org/10.2174/092986709788186147)]
16. **Ricci-Vitiani L**, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. *Nature* 2007; **445**: 111-115 [PMID: 17122771 DOI: 10.1038/nature05384]
17. **O’ Brien CA,** Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 2007; **445**: 106-110 [PMID: 17122772 DOI: 10.1038/nature05372]
18. **Dalerba P,** Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci USA* 2007; **104**: 10158-10163 [PMID: 17548814 DOI: 10.1073/pnas.0703478104]
19. **Sagiv E,** Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. *Gastroenterology* 2006; **131**: 630-639 [PMID: 16890615 DOI: 10.1053/j.gastro.2006.04.028]
20. **Fujimoto K**, Beauchamp RD, Whitehead RH. Identification and isolation of candidate human colonic clonogenic cells based on cell surface integrin expression. *Gastroenterology* 2002; **123**: 1941–1948 [PMID: 12454851 DOI: 10.1053/gast.2002.37065]
21. **Barker N**, Clevers H. Leucine-rich repeat-containing G-protein-coupled receptors as markers of adult stem cells. *Gastroenterology* 2010; **138**: 1681-1696 [PMID: 20417836 DOI: 10.1053/j.gastro.2010.03.002]
22. **Miraglia S,** Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. *Blood* 1997; **90**: 5013-5021 [PMID: 9389721]
23. **Asahara T,** Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B,Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997; **275**: 964–967 [PMID: 9020076 DOI: 10.1126/science.275.5302.964]
24. **Shaked Y,** Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. *Science* 2006; **313**: 1785–1787 [PMID: 16990548 DOI: 10.1126/science.1127592]
25. **Grosse-Gehling P,** Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-Schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. *J Pathol* 2013; **229**: 355-378 [PMID: 22899341 DOI: 10.1002/path.4086]
26. **Puglisi MA,** Sgambato A, Saulnier N, Rafanelli F, Barba M, Boninsegna A, Piscaglia AC, Lauritano C, Novi ML, Barbaro F, Rinninella E, Campanale C, Giuliante F, Nuzzo G, Alfieri S, Doglietto GB, Cittadini A, Gasbarrini A. Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. *Eur Rev Med Pharmacol Sci* 2009; **13** Suppl 1: 55-62 [PMID: 19530513]
27. **Marzesco AM,** Janich P, Wilsch-Bräuninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. *J Cell Sci* 2005; **118**: 2849-2858 [PMID: 15976444 DOI: 10.1016/j.febslet.2009.01.048]
28. **Sgambato A,** Puglisi MA, Errico F, Rafanelli F, Boninsegna A, Rettino A, Genovese G, Coco C, Gasbarrini A, Cittadini A. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. *J Cell Physiol* 2010; **224**: 234-241 [PMID: 20333645 DOI: 10.1002/jcp.22124]
29. **Shmelkov SV,** Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors*. J Clin* *Invest* 2008; **118**: 2111-2120 [PMID: 18497886 DOI: 10.1172/JCI34401]
30. **Feng JM,** Miao ZH, Jiang Y, Chen Y, Li JX, Tong LJ, Zhang J, Huang YR, Ding J. Characterization of the conversion between CD133+ and CD133- cells in colon cancer SW620 cell line. *Cancer Biol Ther* 2012; **13**: 1396-1406 [PMID: 22954703 DOI: 10.4161/cbt.22000]
31. **Hsu CS,** Tung CY, Yang CY, Lin CH. Response to stress in early tumor colonization modulates switching of CD133-positive and CD133-negative subpopulations in a human metastatic colon cancer cell line, SW620. *PLoS One* 2013; **8**: e61133[PMID: 23577199 DOI: 10.1371/journal.pone.0061133]
32. **Kojima M,** Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. *Cancer Sci* 2008; **99**: 1578-1583[PMID: 18754869 DOI: 10.1111/j.1349-7006.2008.00849.x]
33. **Horst D,** Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. *Br J Cancer* 2008; **99**: 1285-1289 [PMID: 18781171 DOI: 10.1038/sj.bjc.6604664]
34. **Ong CW,** Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. *Mod Pathol* 2010; **23**: 450-457 [PMID: 20081809 DOI: 10.1038/modpathol.2009.181]
35. **Kawamoto A,** Tanaka K, Saigusa S, Toiyama Y, Morimoto Y, Fujikawa H, Iwata T, Matsushita K, Yokoe T, Yasuda H, Inoue Y, Miki C, Kusunoki M. Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy. *Exp Ther Med* 2012; **3**: 403-409 [PMID: 22969903 DOI: [10.3892/etm.2011.438](http://dx.doi.org/10.3892/etm.2011.438)]
36. **Chao C,** Carmical JR, Ives KL, Wood TG, Aronson JF, Gomez GA, Djukom CD, Hellmich MR.CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133- cells*. Lab Invest* 2012; **92**: 420-436 [PMID: 22157717 DOI: 10.1038/labinvest.2011.185]
37. **Zhang SS,** Han ZP, Jing YY, Tao SF, Li TJ, Wang H, Wang Y, Li R, Yang Y, Zhao X, Xu XD, Yu ED, Rui YC, Liu HJ, Zhang L, Wei LX. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. *BMC Med* 2012; **10**: 85 [PMID: 22871210 DOI: 10.1186/1741-7015-10-85]
38. **Kemper K,** Versloot M, Cameron K, Colak S, de Sousa e Melo F, de Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J, Medema JP. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. *Clin Cancer Res* 2012; **18**: 3132-3141 [PMID: 22496204 DOI: 10.1158/1078-0432.CCR-11-3066]
39. **Mohammadi M,** Bzorek M, Bonde JH, Nielsen HJ, Holck S. The stem cell marker CD133 is highly expressed in sessile serrated adenoma and its borderline variant compared with hyperplastic polyp. *J Clin Pathol* 2013; **66**: 403-408 [PMID: 23436931 DOI: 10.1136/jclinpath-2012-201192]
40. **Coco C,** Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, Rizzo G, Bonetti LR, Genovese G, Stigliano E, Cittadini A, Sgambato A. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients*. J* *Exp Clin Cancer Res* 2012; **31**: 71 [PMID: 22964035 DOI: 10.1186/1756-9966-31-71]
41. **Sgambato A**, Errico F, Caredda E, Puglisi MA, Cittadini A. Divergent expression of CD133 in different studies: the need for a consensus panel? *Int* *J Cancer* 2011; **128**: 2247-2249 [PMID: 20626045 DOI: 10.1002/ijc.25551]
42. **Zhu L**, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. *Nature* 2009; **457**: 603-607 [PMID: 19092805 DOI: 10.1038/nature07589]
43. **Arena V,** Caredda E, Cufino V, Stigliano E, Scaldaferri F, Gasbarrini A, Cittadini A, Sgambato A. Differential CD133 expression pattern during mouse colon tumorigenesis. *Anticancer Res* 2011; **31**: 4273-4275 [PMID: 22199291]
44. **Sgambato A**, Corbi M, Svelto M, Caredda E, Cittadini A. New Insights into the CD133 (Prominin-1) Expression in Mouse and Human Colon Cancer Cells. *Adv Exp Med Biol* 2013; **777**: 145-166 [PMID: 23161081 DOI: 10.1007/978-1-4614-5894-4\_10]
45. **Wei Y,** Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, Cao B, Liu C, Wu G, Ao H, Zhang X, Jiang J. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. *Proc Natl Acad Sci USA* 2013; **110**: 6829-6834 [PMID: 23569237 DOI: 10.1073/pnas.1217002110]
46. **Wang YK,** Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S, Huang J.Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. *Carcinogenesis* 2010; **31**: 1376-1380 [PMID: 20530554 DOI: 10.1093/carcin/bgq120]
47. **Wang JY,** Chang CC, Chiang CC, Chen WM, Hung SC. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. *J Cell* *Biochem* 2012; **113**: 1733-1743 [PMID: 22213051 DOI: 10.1002/jcb.24043]
48. **Corbo C,** Orrù S, Gemei M, Noto RD, Mirabelli P, Imperlini E, Ruoppolo M, Vecchio LD, Salvatore F. Protein cross-talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity. *Proteomics* 2012; **12**: 2045-2059 [PMID: 22623141 DOI: 10.1002/pmic.201100370]
49. **Ou J**, Deng J, Wei X, Xie G, Zhou R, Yu L, Liang H. Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. *Stem Cell Res* 2013; **11**: 820-833 [PMID: 23811539 DOI: 10.1016/j.scr.2013.05.009]
50. **Mak AB**, Nixon AM, Kittanakom S, Stewart JM, Chen GI, Curak J, Gingras AC, Mazitschek R, Neel BG, Stagljar I, Moffat J. Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. *Cell Rep* 2012; **2**: 951-963 [PMID: 23084749 DOI: 10.1016/j.celrep.2012.09.016]
51. **Baba Y,** Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. *Am J Pathol* 2010; **176**: 2292-2230 [PMID: 20363910 DOI: 10.2353/ajpath.2010.090972]
52. **Ohnishi S,** Maehara O, Nakagawa K, Kameya A, Otaki K, Fujita H, Higashi R, Takagi K, Asaka M, Sakamoto N, Kobayashi M, Takeda H. Hypoxia-Inducible Factors Activate CD133 Promoter through ETS Family Transcription Factors. *PLoS One* 2013; **8**: e66255 [PMID: 23840432 DOI: 10.1371/journal.pone.0066255]
53. **Mao Q,** Zhang Y, Fu X, Xue J, Guo W, Meng M, Zhou Z, Mo X, Lu Y.A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy. *J Cancer Res Clin Oncol* 2013; **139**: 211-222 [PMID: 23052691 DOI: 10.1007/s00432-012-1310-3]
54. **Yi JM,** Tsai HC, Glöckner SC, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. *Cancer Res* 2008; **68**: 8094-8103 [PMID: 18829568 DOI: 10.1158/0008-5472.CAN-07-6208 ]
55. **Screaton GR,** Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. *Proc Natl Acad Sci USA* 1992; **89**: 12160-12164 [PMID: 1465456 DOI: [10.1073/pnas.89.24.12160](http://dx.doi.org/10.1073/pnas.89.24.12160)]
56. **Sneath RJ,** Mangham DC. The normal structure and function of CD44 and its role in neoplasia*. Mol Pathol* 1998; **51**: 191–200 [PMID: 9893744 DOI: [10.1136/mp.51.4.191](http://dx.doi.org/10.1136/mp.51.4.191)]
57. **Nagano O,** Saya H. Mechanism and biological significance of CD44 cleavage. *Cancer Sci* 2004; **95**: 930-935 [PMID: 15596040 DOI: 10.1111/j.1349-7006.2004.tb03179.x]
58. **Du L,** Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q. CD44 is of functional importance for colorectal cancer stem cells. *Clin Cancer Res* 2008; **14**: 6751–6760 [PMID: 18980968 DOI: 10.1158/1078-0432.CCR-08-1034]
59. **Fan CW**, Chen T, Shang YN, Gu YZ, Zhang SL, Lu R, Ouyang SR, Zhou X, Li Y, Meng WT, Hu JK, Lu Y, Sun XF, Bu H, Zhou ZG, Mo XM. Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies. *Cell Death Dis* 2013; **4**: e828 [PMID: 24091671 DOI: 10.1038/cddis.2013.337]
60. **Zeilstra J,** Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and Cancer Stem Cell Marker CD44 in Apc (Min/+) Mice attenuates intestinal tumorigenesis. *Cancer Res* 2008; **68**: 3655-3661 [PMID: 18483247 DOI: 10.1158/0008-5472.CAN-07-2940]
61. **Harada N,** Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, Matsuno S. Introduction of antisense CD44s cDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. *Int J Cancer* 2001; **91**: 67–75 [PMID: 11149422 DOI: 10.1002/1097-0215(20010101)91:1<67::AID-IJC1011>3.0.CO;2-D]
62. **Dallas MR,** Liu G, Chen WC, Thomas SN, Wirtz D, Huso DL, Konstantopoulos K. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. *FASEB* *J* 2012; **26**: 2648-2656 [PMID: 22415308 DOI: 10.1096/fj.12-203786]
63. **Ropponen KM,** Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. *Scand J* *Gastroenterol* 1998; **33**: 301-309 [PMID: 9548625 DOI: [10.1080/00365529850170900](http://dx.doi.org/10.1080/00365529850170900)]
64. **Ylagan LR,** Scholes J, Demopoulos R. CD44: a marker of squamous differentiation in adenosquamous neoplasms. *Arch Pathol Lab Med* 2000; **124**: 212-215 [PMID: 10656728]
65. **Fernández JC,** Vizoso FJ, Corte MD, Gava RR, Corte MG, Suárez JP, García-Muñíz JL, García-Morán M. CD44s expression in resectable colorectal carcinomas and surrounding mucosa. *Cancer Invest* 2004; **22**: 878-885 [PMID: 15641486 DOI: [10.1081/CNV-200039658](http://dx.doi.org/10.1081/CNV-200039658)]
66. **Huh JW,** Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, Joo JK. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. *Pathol Int* 2009; **59**: 241-246 [PMID: 19351367 DOI: 10.1111/j.1440-1827.2009.02357.x]
67. **Lugli A**, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. *Br J Cancer* 2010; **103**: 382-390 [PMID: 20606680 DOI: 10.1038/sj.bjc.6605762]
68. **Herlyn M,** Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. *Proc Natl Acad Sci USA* 1979; **76**: 1438-1442 [PMID: 286328 DOI: [10.1073/pnas.76.3.1438](http://dx.doi.org/10.1073/pnas.76.3.1438)]
69. **Went P,** Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. *Br J Cancer* 2006; **94**: 128-135 [PMID: 16404366 DOI: 10.1038/sj.bjc.6602924]
70. **Baeuerle PA**, Gires O. EpCAM (CD326) finding its role in cancer. *Br J Cancer* 2007; **96**: 417-423 [PMID: 17211480 DOI: 10.1038/sj.bjc.6603494]
71. **Trzpis M**, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. *Am J Pathol* 2007; **171**: 386-395 [PMID: 17600130 DOI: [10.2353/ajpath.2007.070152](http://dx.doi.org/10.2353/ajpath.2007.070152)]
72. **Denzel S**, Maetzel D, Mack B, Eggert C, Bärr G, Gires O. Initial activation of EpCAM cleavage via cell-to-cell contact. *BMC Cancer* 2009; **9**: 402 [PMID: 19925656 DOI: 10.1186/1471-2407-9-402]
73. **Balzar M,** Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV. The structural analysis of adhesions mediated by Ep-CAM. *Exp Cell Res* 1999; **246**: 108-121[PMID: 9882520 DOI: [10.1006/excr.1998.4263](http://dx.doi.org/10.1006/excr.1998.4263)]
74. **Ralhan R,** He HC, So AK, Tripathi SC, Kumar M, Hasan MR, Kaur J, Kashat L, MacMillan C, Chauhan SS, Freeman JL, Walfish PG. Nuclear and cytoplasmic accumulation of Ep- ICD is frequently detected in human epithelial cancers. *PLoS One* 2010; **5**: e14130 [PMID: 21152431 DOI: 10.1371/journal.pone.0014130]
75. **Dylla SJ**, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. *PLoS One* 2008; **3**: e2428 [PMID: 18560594 DOI: 10.1371/journal.pone.0002428]
76. **Kristiansen G,** Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. *J Mol Histol* 2004; **35**: 255-262 [PMID: 15339045 DOI: [10.1023/B:HIJO.0000032357.16261.c5](http://dx.doi.org/10.1023/B%3AHIJO.0000032357.16261.c5)]
77. **Nestl A**, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. *Cancer* *Res* 2001; **61**: 1569-1577 [PMID: 11245467]
78. **Weichert W**, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. *Clin Cancer Res* 2005; **11**: 6574-6581 [PMID: 16166435 DOI: 10.1158/1078-0432.CCR-05-0606]
79. **Choi D,** Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. *World J Gastroenterol* 2009; **15**: 2258-2264 [PMID: 19437567 DOI: [10.3748/wjg.15.2258](http://dx.doi.org/10.3748/wjg.15.2258)]
80. **Yeung TM**, Gandhi SC, Wilding JL, Muschel R, Bodmer WF.Cancer stem cells from colorectal cancer-derived cell lines. *Proc Natl Acad Sci USA* 2010; **107**: 3722-3727 [PMID: 20133591 DOI: 10.1073/pnas.0915135107]
81. **Muppala S**, Mudduluru G, Leupold JH, Buergy D, Sleeman JP, Allgayer H. CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. *PLoS One* 2013; **8**: e59563 [PMID: 23533633 DOI: 10.1371/journal.pone.0059563]
82. **Brizzi MF**, Tarone G, Defilippi P. Extracellular matrix, integrins, and growth factors as tailors of the stem cell niche. *Curr Opin Cell Biol* 2012; **24**: 645–651 [PMID: 22898530 DOI: 10.1016/j.ceb.2012.07.001]
83. **Hynes RO**. Integrins: bidirectional, allosteric signaling machines. *Cell* 2002; **110**: 673-687 [PMID: 12297042 DOI: [10.1016/S0092-8674(02)00971-6](http://dx.doi.org/10.1016/S0092-8674%2802%2900971-6)]
84. **Pignatelli M,** Liu D, Nasim MM, Stamp GW, Hirano S, Takeichi M. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells. *Br J* *Cancer* 1992; **66**: 629-634 [PMID: 1384639 DOI: [10.1038/bjc.1992.328](http://dx.doi.org/10.1038/bjc.1992.328)]
85. **Okazaki K**, Nakayama Y, Shibao K, Hirata K, Nagata N, Itoh H. Enhancement of Metastatic Activity of Colon Cancer as Influenced by Expression of Cell Surface Antigens. *J Surg Res* 1998; **78**: 78–84 [PMID: 9733622 [DOI: 10.1006/jsre.1998.5298](http://dx.doi.org/10.1006/jsre.1998.5298)]
86. **Fan LF**, Dong WG , Jiang CQ, Xia D, Liao F, Yu QF. Expression of putative stem cell genes Musashi-1 and β1-integrin in human colorectal adenomas and adenocarcinomas. *Int J* *Colorectal Dis* 2010; **25**:17–23 [PMID: 19714342 DOI: 10.1007/s00384-009-0791-2]
87. **Langan RC**, Mullinax JE, Ray S, Raiji MT, Schaub N, Xin HW, Koizumi T, Steinberg SM, Anderson A, Wiegand G, Butcher D, Anver M, Bilchik AJ, Stojadinovic A, Rudloff U, Avital I. A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers. *J Cancer* 2012; **3**: 231-240 [PMID: 22670157 DOI: 10.7150/jca.4542]
88. **Hongo K**, Tanaka J, Tsuno NH, Kawai K, Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E, Kitayama J, Takahashi K, Nagawa H. CD133(L) Cells, Derived From a Single Human Colon Cancer Cell Line, Are More Resistant to 5-Fluorouracil (FU) Than CD133(D) Cells, Dependent on the b1-Integrin Signaling. *J Surg Res* 2012; **175**: 278–288 [PMID: 21601882 DOI: 10.1016/j.jss.2011.03.076]
89. **Van der Flier LG**, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M ,Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G. The Intestinal Wnt/TCF Signature. *Gastroenterology* 2007; **132**: 628–632 [PMID: 17320548 DOI: [10.1053/j.gastro.2006.08.039](http://dx.doi.org/10.1053/j.gastro.2006.08.039)]
90. **de Lau WB**, Snel B, Clevers HC. The R-spondin protein family. *Genome Biol* 2012; **13**: 242 [PMID: 22439850 DOI: 10.1186/gb-2012-13-3-242]
91. **van de Wetering M**, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell* 2002; **111**: 241-250 [PMID: 12408868 DOI: [10.1016/S0092-8674(02)01014-0](http://dx.doi.org/10.1016/S0092-8674%2802%2901014-0)]
92. **Wu XS**, Xi HQ, Chen L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. *World J Surg Oncol* 2012; **10**: 244 [PMID: 23153436 DOI: 10.1186/1477-7819-10-244]
93. **Haegebarth A**, Clevers H. Wnt signaling, lgr5, and stem cells in the intestine and skin. *Am J Pathol* 2009; **174**: 715-721 [PMID: 19197002 DOI: 10.2353/ajpath.2009.080758]
94. **Takahashi H**, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, Yokobori T, Mimori K, Yamamoto H, Sekimoto M, Doki Y, Mori M. Significance of Lgr5 (+ve) cancer stem cells in the colon and rectum. *Ann Surg Oncol* 2011; **18**: 1166–1174 [PMID: 21125339 DOI: 10.1245/s10434-010-1373-9]
95. **Batlle E**, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M,Pawson T, Clevers H. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. *Cell* 2002; **111**: 251–263 [PMID: 12408869 DOI: [10.1016/S0092-8674(02)01015-2](http://dx.doi.org/10.1016/S0092-8674%2802%2901015-2)]
96. **Lehmann JM**, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. *Proc Natl Acad Sci USA* 1989; **86**: 9891-9895 [PMID: 2602381 DOI: 10.1073/pnas.86.24.9891]
97. **Aruffo A**, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe, JA, Bajorath J. CD6- ligand interactions: a paradigm for SRCR domain function? *Immunol Today* 1997; **18**: 498-504 [PMID: 9357143 DOI: [10.1016/S0167-5699(97)01130-4](http://dx.doi.org/10.1016/S0167-5699%2897%2901130-4)]
98. **Weidle UH**, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. *Cancer Genomics Proteomics* 2010; **7**: 231-243 [PMID: 20952758]
99. **Levin TG,** Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, Swain JR, Wong MH. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. *Gastroenterology* 2010; **139**: 2072-2082 [PMID: 20826154 DOI: 10.1053/j.gastro.2010.08.053]
100. **Weichert W**, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival*. J Clin Pathol* 2004; **57**: 1160-1164 [PMID: 15509676 DOI: 10.1136/jcp.2004.016238]
101. **Horst D,** Kriegl L, Engel J. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. *Cancer Invest* 2009; **27**: 844 [PMID: b19626493 DOI: 10.1080/07357900902744502]
102. **Tachezy M**, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR, Bockhorn M. Activated leukocyte cell adhesion molecule (CD166)–its prognostic power for colorectal cancer patients. *J* *Surg Res* 2012; **177**: e15–e20 [PMID: 22482754 DOI: 10.1016/j.jss.2012.02.013]
103. **Frank NY**, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. *J Clin Invest* 2010; **120**: 41-50 [PMID: 20051635 DOI: 10.1172/JCI41004]
104. **Todaro M**, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. *Cell Stem Cell* 2007; **1**: 389-402 [PMID: 18371377 DOI: 10.1016/j.stem.2007.08.001]
105. **Dallas NA**, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. *Cancer Res* 2009; **69**: 1951-1957 [PMID: 19244128 DOI: 10.1158/0008-5472.CAN-08-2023]
106. **Bach P**, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. *Cancer Res* 2013; **73**: 865-874 [PMID: 23293278 DOI: 10.1158/0008-5472.CAN-12-2221]
107. **Bostad M**, Berg K, Høgset A, Skarpen E, Stenmark H, Selbo PK. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties. *J Control Release* 2013; **168**: 317-326 [PMID: 23567040 DOI: 10.1016/j.jconrel.2013.03.023]
108. **Chen H**, Luo Z, Sun W, Zhang C, Sun H, Zhao N, Ding J, Wu M, Li Z, Wang H. Low glucose promotes CD133mAb-elicited cell death via inhibition of autophagy in hepatocarcinoma cells. *Cancer Lett* 2013; **336**: 204-212 [PMID: 23652197 DOI: 10.1016/j.canlet.2013.04.031]
109. **Swaminathan SK**, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. *J Control* *Release* 2013; **171**: 280-287 [PMID: 23871962 DOI: 10.1016/j.jconrel.2013.07.014]
110. **Riethmüller G**, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, . Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. *Lancet* 1994; **343**: 1177-1183 [PMID: 7909866 DOI: 10.1016/S0140-6736(94)92398-1]
111. **Punt CJ**, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. *Lancet* 2002; **360**: 671-677 [PMID: 12241873 DOI: [10.1016/S0140-6736(02)09836-7](http://dx.doi.org/10.1016/S0140-6736%2802%2909836-7)]
112. **Fields AL**, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A, Schulz J, Eisenberg P, Forster J, Wissel P. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. *J Clin Oncol* 2009; **27**: 1941-1947 [PMID: 19273708 DOI: 10.1200/JCO.2008.18.5710]
113. **Waldron NN**, Barsky SH, Dougherty PR, Vallera DA. A bispecific EpCAM/CD133- targeted toxin is effective against carcinoma. *Target Oncol* 2013 [PMID: 23900680]
114. **Misra S**, Hascall VC, De Giovanni C, Markwald RR, Ghatak S.Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. *J Biol Chem* 2009; **284**: 12432-12446 [PMID: 19246453 DOI: 10.1074/jbc.M806772200]
115. **Nautiyal J**, Kanwar SS, Yu Y, Majumdar AP. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. *J Mol Signal* 2011; **6**: 7 [PMID: 21774804 DOI: 10.1186/1750-2187-6-7]
116. **Kanwar SS**, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH, Majumdar AP. Difluorinated-Curcumin (CDF): A Novel Curcumin Analog is a Potent Inhibitor of Colon Cancer Stem-Like Cells. *Pharm Res* 2011; **28**: 827-838 [PMID: 21161336 DOI: 10.1007/s11095-010-0336-y]
117. **Yu M**, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. *Nanoscale* 2013; **5**: 178-183 [PMID: 23076766 DOI: 10.1039/c2nr32145a]
118. **Sagiv E**, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. *Cancer Res* 2008; **68**: 2803-2812 [PMID: 18413748 DOI: 10.1158/0008-5472.CAN-07-6463]
119. **Park JJ**, Seo SM, Kim EJ, Lee YJ, Ko YG, Ha J, Lee M. Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin b1 signaling. *Biochem Biophys Res Commun* 2012; **426**: 461–467 [PMID: 22943849 DOI: 10.1016/j.bbrc.2012.08.091]
120. **Behrens J**, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. *Nature* 1996; **382**: 638–642 [PMID: 8757136 DOI: 10.1038/382638a0]
121. **Chen B**, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, Lum L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. *Nat Chem Biol* 2009; **5**: 100–107 [PMID: 19125156 DOI: 10.1038/nchembio.137]
122. **Huang SM**, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M,Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. *Nature* 2009; **461**: 614–620 [PMID: 19759537 DOI: 10.1038/nature08356]
123. **Thorne CA**, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, Kim K, Melancon B, Ghidu VP, Sulikowski GA, LaFleur B, Salic A, Lee LA, Miller DM 3rd, Lee E. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. *Nat Chem Biol* 2010; **6**: 829–836 [PMID: 20890287 DOI: 10.1038/nchembio.453]
124. **Gonsalves FC**, Klein K, Carson BB, Katz S, Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM, DasGupta R. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. *Proc Natl Acad Sci USA* 2011; **108**: 5954–5963 [PMID: 21393571 DOI: 10.1073/pnas.1017496108 ]
125. **Emami KH**, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR, Kahn M. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. *Proc Natl Acad Sci USA* 2004; **101**: 12682–12687 [PMID: 15314234 DOI: 10.1073/pnas.0404875101]
126. **Takahashi-Yanaga F**, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? *Clin Cancer Res* 2010; **16**: 3153–3162 [PMID: 20530697 DOI: 10.1158/1078-0432.CCR-09-2943]
127. **He B**, You L Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. *Neoplasia* 2004; **6**: 7–14 [PMID: 15068666]
128. **Ueno K**, Hazama S, Mitomori S, Nishioka M, Suehiro Y, Hirata H, Oka M, Imai K, Dahiya R, Hinoda Y. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. *Br J Cancer* 2009; **101**: 1374–1381 [PMID: 19773752 DOI: 10.1038/sj.bjc.6605307]
129. **Anastas JN**, Moon RT. WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer* 2013; **13**: 11-26 [PMID: 23258168 DOI: 10.1038/nrc3419]
130. **Hoey T**, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A Satyal S,Wang X,Clarke MF, Lewicki J, Gurney A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. *Cell Stem Cell* 2009; **5**: 168–177 [PMID: 19664991 DOI: 10.1016/j.stem.2009.05.019 ]
131. **Fischer M**, Yen WC, Kapoun AM, Wang M, O’ Young G, Lewicki J, Gurney A, Hoey T. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. *Cancer Res* 2011; **71**: 1520–1525 [PMID: 21193546 DOI: 10.1158/0008-5472.CAN-10-2817]

**P-Reviewers:** Dittmar T, Li YC, Bueno V, Zhang Q **S-Editor:** Cui XM

**L-Editor: E-Editor:**

**Figure 1 Schematic representation of an individual colon crypt showing the position of different cell types.** Stem cells lie at the bottom of the crypt and through an asymmetric division are responsible for generating all epithelial cell types along the crypt-villus axis.

**Figure 2 Models of tumor development**. (A) Stochastic model: every cancer cell isolated from the bulk tumor is tumorigenic and thus has the ability to proliferate extensively and initiate tumor growth. (B) Cancer stem cell model: only a rare subpopulation of undifferentiated cells has the unique biological properties necessary for tumor initiation, maintenance, and spreading.

**Figure 3 Advantages o**f a cancer stem cell**-specific therapy compared to conventional anticancer therapies**. The current anticancer drugs wipe out most of the bulk population but the surviving CSCs can repopulate the tumor. Specific targeting of CSCs is essential for regression and complete eradication of the tumor. CSCs: Cancer stem cells.

**Figure 4 Schematic representation of the CD133 molecule.** CD133 consists of an extracellular N-terminal domain, a cytoplasmic C-terminus containing five tyrosine residues, two small cysteine-rich cytoplasmic loops and two large extracellular loops, each containing four consensus sequences for N-linked glycosilation.

**Figure 5 Signals regulating CD133 expression levels.** The exposure to environmental stress, hypoxia and cell-adhesion-free condition promotes switching of CD133- to CD133+ cells while exposure to ECM components promotes switching of CD133+ to CD133- cells.

**Figure 6 Possible role of the interaction between CXCR4/CD133 cancer cells and SDF-1 ligands**. The SDF-1 ligand secreted by carcinoma-associated fibroblasts (CAF) in tumor microenvironment interacts with CXCR4/CD133 expressing cancer cells and could drive primary tumor cells towards metastatic sites.

**Figure 7 Epitopes recognized by different antibodies on CD133 molecule.**

**Figure 8 Potential molecular pathway associated with CD133*.*** The phosphorylation of the tyrosine 828 is involved in the binding to p85 (PI3K regulatory subunit) and in the subsequent activation of PI3K/Akt pathway, which, finally, promotes the self-renewal and tumor formation of CSCs. CSCs: Cancer stem cells.

**Figure 9 Schematic representation of HDAC6-mediated regulation of CD133 expression**. HDAC6 physically binds to CD133 and stabilizes the â-catenin that in the nucleus promotes the activation of its target genes.

**Figure 10 Schematic representation of CD44 sequential proteolytic processing.** CD44 undergoes sequential proteolytic cleavages in the ectodomain and intramembranous domain. Cleavage of CD44 ectodomain generates soluble CD44 that regulates cell attachment and migration and induces the intramembranous domain cleavage, releasing the intracellular domain of CD44 (CD44-ICD). CD44-ICD translocates to the nucleus, where it activates gene transcription, including CD44 itself, via binding to TPA-responsive elements (TRE).

**Figure 11 Schematic representation of EpCAM activation**. Cleavage of full length EpCAM generates EpEx (extracellular domain of EPCAM) andEpICD (EpCAM Intracellular Domain) fragments. EpICD binds the scaffold protein FHL2 and joins to the transcriptional regulators â-catenin and, within the nucleus, interacts with LEF, binds to DNA and induces gene activation.

**Figure 12** **Origin of cancer stem cells and tumor heterogeneity.** It has been hypothesized that CSCs may derive from transformation of quiescent, normal stem cells (left) or could result from the de-differentiation of more mature cells which might re-acquire the capability of self-renewal. Other mutations might occur following transformation in both cases. SC: Stem cell; PC: Progenitor cell; DC: Differentiated cell; C: Cancer; N: Normal; CSCs: Cancer stem cells.

**Table 1 Cell surface and intracellular molecules suggested as putativ**e cancer stem cell **markers in colorectal cancer and their most important features**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Marker** | **Other name** | **Gene location1** | **Function** | **References** |
| CD133 | Prominin-1, AC133 | Chr 4 (p15.32) | Encoding of a pentaspan transmembrane glycoprotein wich binds cholesterol in cholesterol-containing plasma membrane microdomains | 22 |
| CD44 | PGP-1, HUTCH-1, GP90, EPICAN, CDW44, MIC4 | Chr 11 (p13) | Cell adhesion molecule;involved in lymph node homing and lymphocyte activation | 55, 56 |
| EpCAM | ESA, CD326, MK- 1, KSA, HEA125, BerEp4, 17-1A, GA733-2, KS1/4, EGP-2, EGP34, TROP-1 | Chr 2 (p21) | Epithelial cell adhesion molecule | 70 |
| CD24 | HSA | Chr 6 (q21) | Mucin-like cell adhesion molecule  | 76 |
| CD29 | Β1 Integrin | Chr 10 (p11.2) | Receptor for extracellular matrix proteins;involved in regulation of cell migration, proliferation, survival, differentiation and death | 82 |
| Lgr5 | GPR49 | Chr 12 (q22-q23) | Receptor for R-spondin proteins;marker for adult stem cells | 89, 90 |
| CD166 | ALCAM | Chr 3 (q13.1) | Cell adhesion molecule | 96 |

1From http://www.ncbi.nlm.nih.gov/gene.

**Table 2 Prognostic value of CD133**

|  |  |  |
| --- | --- | --- |
| Marker | Prognostic value | References |
| CD133 | Worse outcome and higher risk of metastasisIndependent prognostic marker for overall survivalAssociation with CSC resistance to 5FU-based chemotherapy in CRCAssociation with resistance to conventional radiotherapy in CRCPrediction of distant recurrences after chemoradiotherapy in colon cancer patientsHigh tumorigenicity of CD133+ CRC cells compared to CD133- cells due to their interaction with CAFs by paracrine signaling axis of CXCR4-SDF1Risk factor for poor overall survival in stage II and III in colon cancer patientsRelationship with K-Ras and B-Raf mutations in CRC patients | [32][33][34][35][35][36][37][38] |

CSC: Cancer stem cell; CRC: Colorectal cancer.

**Table 3 Prognostic value of CD44**

|  |  |  |
| --- | --- | --- |
| Marker | Prognostic value | References |
| CD44 | Association of CD44 downregulation with a lower metastatic potential of CRC cellsAssociation of CD44 downregulation with a higher metastatic and migratory potential of CRC cellsAssociation with a reduced survivalCorrelation of CD44 loss with a higher tumor aggressivenessRelation with CRC cells proliferation but not with patients outcomeAssociation with lymph node involvement and invasion depthUnfavorable prognostic factor for overall survival in advanced CRCCorrelation of CD44 loss with advanced tumor stage, vascular invasion, lymph node involvement and infiltrating tumor borderAssociation of CD44 loss in the lesion invasive front with adverse outcome of CRC patients | [61][62][63][64][65][66][66][67][67] |

CRC: Colorectal cancer.